| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Pulmonary fibrosis is a progressive and lethal lung disease characterized by the accumulation of extracellular matrix, loss of pulmonary function, and change in lung structure. In this study, the intrapulmonary pharmacokinetics of aerosolized drugs was evaluated using animal models of bleomycin induced pulmonary fibrosis. This study suggests that in pulmonary fibrosis, aerosolized drugs cannot distribute widely in the lung and can easily leak into the plasma because of their accumulation in the extracellular matrix and destruction of the epithelial tight junctions in lungs.In addition, we assessed the delivery of anti-fibrotic agents incorporated into liposomes modified with truncated bFGF and investigated the anti-fibrotic effect of the drug. This study indicates that tbFGF-liposomes with 100 nm are useful drug delivery system of anti-fibrotic agents to fibrotic lesion for the treatment of idiopathic pulmonary fibrosis.
|
